Will new treatments decrease potential participants for ongoing and future research? In a world where more efficient and better targeted treatments are being approved at an unprecedented rate, patients are understandably eager to take advantage of the new discoveries, especially when it comes to rare diseases such as Immunoglobulin A nephropathy (IgAN) where safe and […]
Read More
Patient-centricity is the key to more successful research and adoption of new treatments. ASCO’s 2023 Annual Meeting drew oncology professionals from around the world to learn about new clinical advances in cancer research, gain real-time insights from world-renowned experts and connect with one of the largest, most diverse audiences in global oncology. Peer-to-peer interaction is the […]
Read MoreHaving recently attended the World Congress of Nephrology (WCN) in Bangkok, Thailand, George Clinical representatives had the opportunity to meet experts and peers from around the world to share ideas and best practices and continue to develop networks that will advance global kidney health. Connecting with communities from different parts of the world not only highlights […]
Read MoreA deeper understanding of disease mechanisms will help address a growing global problem. Chronic kidney disease (CKD) is a global health crisis with an estimated 850 million people affected worldwide. Rising faster than all non-infectious diseases including cardiovascular disease, CKD is 20 times more prevalent than cancer. Most people don’t even realize their kidneys are […]
Read More
George Clinical Represented at AusBiotech 2022 Conference in Perth. Australia is a world-leading location for the life sciences and has been ranked among the top five in biotechnology innovation for the third consecutive year. AusBiotech is Australia’s life sciences organization, working on behalf of a well-connected network of over 3,000 members for more than 35 […]
Read MoreThat leaves 80% of mBC patients with fewer treatment options. However, research has shown that 55%-60% of these actually express low levels of HER2, and this is the category that Destiny-04 targeted, demonstrating that the legacy cutoff point to determine HER2 positivity can now be extended. These results establish HER2-low metastatic breast cancer as a […]
Read More
COVID era innovations will help shape the future for more equitable representation. Oncology professionals from around the world attended the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in June, one of the largest oncology research conferences of the year. Researchers presented breakthrough clinical trial data including new treatment options, symptom management and research […]
Read MoreMillions of screenings and treatments have been missed resulting in a rise in metastatic cancers. Cancer survivorship has made great strides, with death rates declining 31% since 1991 and oncology clinical trials dominating therapeutic focus. But cancer patients require uninterrupted care, and the full impact on survivorship of disruptions in care caused by the pandemic […]
Read MoreCOVID-19 propels clinical trial innovations from prolonged conjecture to a paradigm shift. Between March and November of 2020, COVID-19 negatively affected more than 1,200 clinical trials worldwide. Some were shut down completely while others were affected by lockdowns, patients becoming reluctant to continue with a trial or a host of other pandemic-related interruptions. As in […]
Read MoreWritten by Maria Ali in collaboration with Suzanna Phelps-Fredette Medical history began with a holistic approach Medical philosophy and practice dates back to the Indian Ayurvedic system of medicine and ancient Greek, Roman and Islamic physicians. Both took a holistic approach that considered the physical, mental and emotional health of a person as well as […]
Read More
